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Abstract
Introduction: RhoB has been reported to exert positive and negative effects on cancer pathophysiology but an
understanding of its role in breast cancer remains incomplete. Analysis of data from the Oncomine database
showed a positive correlation between RhoB expression and positivity for both estrogen receptor alpha (ERa) and
progesterone receptor (PR).
Methods: This finding was validated by our analysis of a tissue microarray constructed from a cohort of
113 patients and then investigated in human cell models.
Results: We found that RhoB expression in tissue was strongly correlated with ERa and PR expression and
inversely correlated with tumor grade, tumor size and count of mitosis. In human breast cancer cell lines, RhoB
attenuation was associated with reduced expression of both ERa and PR, whereas elevation of RhoB was found to
be associated with ERa overexpression. Mechanistic investigations suggested that RhoB modulates ERa expression,
controlling both its protein and mRNA levels, and that RhoB modulates PR expression by accentuating the
recruitment of ERa and other major co-regulators to the promoter of PR gene. A major consequence of RhoB
modulation was that RhoB differentially regulated the proliferation of breast cancer cell lines. Interestingly, we
documented crosstalk between RhoB and ERa, with estrogen treatment leading to RhoB activation.
Conclusion: Taken together, our findings offer evidence that in human breast cancer RhoB acts as a positive
function to promote expression of ERa and PR in a manner correlated with cell proliferation.
Introduction
Hormone therapy is recommended in breast cancers that
express estrogen receptor alpha (ERa) and/or progester-
one receptor (PR). This therapy is largely effective but
there are nevertheless many cases of systemic resistance.
A number of studies have addressed the question of the
mechanisms of resistance to hormone therapy [1,2]. ERa
transcriptional effects are not only determined by ligands
as estradiol (E2), but also by crosstalk between ERa and
growth factor signaling [3]. The hierarchy among these
associations is not known and various growth factor recep-
tors are likely to be required [3].
Prenylated proteins such as Rho GTPases are key ele-
ments in growth factor signal transduction pathways [4].
A variety of growth factors present in the tumor micro-
environment activate Rho proteins [5], especially RhoB
[6-8]. As a Rho protein, RhoB cycles between GTP and
GDP bound states, forming interactions with a variety of
effectors that modulate activity and influence important
processes in cancer [9]. RhoB, in contrast to its relatives
RhoA and RhoC, has been shown to function as a tumor
suppressor gene on the basis of investigations of geneti-
cally RhoB-deficient strains [10] and in human cancer
cells [11-13]. RhoB is an immediate early response gene
that is induced by a variety of stimuli, including growth
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factors [6,14-21]. Although no mutation of Rho GTPases
have been detected in human tumors, a correlation has
been demonstrated between Rho protein overexpression
and poor clinical outcome in breast cancers [22]. RhoB
overexpression has been correlated to disease progression
[23], although this is a controversial issue [24], and over-
expression of guanine exchange factors (GEF) for Rho
GTPases have been correlated to prognosis in breast can-
cers [25]. Indeed, breast tumor progression is accompa-
nied by a decrease in expression of the pro-oncogenic
RhoGEF Tiam1 [26]. Moreover, expression of Rho-GDI
a, a negative regulator of Rho proteins, is reported to
correlate with the outcome of patients with breast cancer
treated by adjuvant chemotherapy [27]. From a molecular
point of view, scaffold proteins involved in Rho functions,
such as Rho-GDI or Dblx, have been observed as part of
ERa-containing complexes [28,29] with direct interaction
between ERa and Rho-GDI [30].
Besides the suggested specific involvement of RhoB in
ER signaling, there have been no detailed investigations
in breast cancer cells, including the assessment of any
correlation with the expression of hormone receptors in
tumors. A major goal of the present study was therefore
to determine the involvement of RhoB in hormone-
dependent breast cancers and to investigate hypothesized
crosstalks between RhoB and ERa signaling.
Materials and methods
Immunohistochemical analysis of tissue microarrays
A tissue microarray was constructed from the 113
patients described in Table S1 in Additional file 1. As
detailed in Additional file 2, the clinical trial was con-
ducted about 30 years ago with no consent required at
that time. Cores (600 μm diameter) of histologically con-
firmed invasive breast carcinomas were extracted from
the original paraffin blocks and re-embedded into a
gridded recipient paraffin block using a tissue arrayer
(Alphelys; Beecher Inc., Plaisir, France). For each case,
three tumor cores and one normal breast core were
taken from the original block.
Tissue microarray immunostaining was performed on a
Techmate Horizon™ slide processor (Dako, Trappes,
France { }). Sections were incubated with antibodies to
ERa (NCL-L-ER-6F11; Novocastra, Nanterre, France), PR
(PgR636 clone; Dako) and RhoB (sc-180; Santa Cruz Bio-
technology, Heidelberg, Germany). The ERa and PR status
was classified by immunohistochemistry expression as
positive (≥ 10% immunoreactive cells) or negative (< 10%
immunoreactive cells), according to the standards applied
in France, as recommended by the Groupe d’Evaluation
des Facteurs Pronostiques par Immunohistochimie dans
les Cancers du Sein. RhoB immunostaining was analyzed
by evaluation of the percentage of tumor-stained cells and
staining intensity, allowing assessment of an ImmunoR-
eactive Score:
IRS = % score × intensity score
Correlation of RhoB expression with clinical variables
was assessed using Mann-Whitney and Spearman’s rank
tests. Univariate survival analysis was performed for dis-
ease-free survival by applying the log-rank test to RhoB
expression levels stratified by median value. The Kaplan-
Meier method was used to link the disease-free survival
according to RhoB expression in the tumors.
Cell culture and reagents
The human breast adenocarcinoma cell lines MCF-7,
ZR75, T47D, SK-BR-3 and MDA-MB-231 were obtained
from the ATCC (Molsheim, France). Cells were grown
routinely in DMEM (Lonza Levallois-Perret, France), sup-
plemented with 5% fetal bovine serum (FBS; Pan-Biotech,
Aidenbach, Germany). Hormonoresistant LCC2 cells (R
Clarke, Karmanos Cancer Center, provided the parent
MCF-7) were grown in F-12 (Lonza) phenol red-free med-
ium, containing 5% dextran-coated charcoal (DCC)-treated
FBS. Cryopreservation of cell cultures ranged from passage
1 to 10. Cells were used for experiments during up to 20
passages. Mouse embryonic fibroblasts (MEFs) were grown
in DMEM with 10% FBS.
Where indicated, cells were deprived of E2 by growing
them in phenol red-free medium containing 5% DCC-
treated FBS. Cells were treated with 50 nM E2 or 50 ng/
ml epidermal growth factor or 2 mM ICI-182, 780
(Sigma-Aldrich Chimie, Lyon, France).
siRNA transfection
Transient transfection of 40 nM siRNA was performed
using Oligofectamine® (Life Technologies - Invitrogen,
Saint Aubin, France) according to the manufacturer’s
instructions. The siRNA sequences of the oligonucleotide
duplexes (Eurogentec, Angers, France) were siB1 (5’-CC
GUCUUCGAGAACUAUGU-dTdT-3’) and siB2 (5’-UGA
UAUCCCUUGUCUGUAA-dTdT-3’), siER (5’-GGGAGA
AUGUUGAAACACA-dTdT-3’) and the nonspecific
sequence siControl (5’-GACGUGGGACUGAAGGGGU-d
TdT-3’).
Adenoviral constructs expressing RhoB and transduction
protocol
Replication-defective (ΔE1, E3) adenoviral vectors expres-
sing RhoB under the transcriptional control of the CMV
promoter were constructed with the Adeasy System
(Qbiogen, Illkirch, France) as described previously [31].
Cells were transduced with adenoviral vectors (control
empty vector or expressing RhoB) at a multiplicity of
infection of 300:1.
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Western blot analysis of human cell lines
Cells were lysed and protein analyzed by SDS-PAGE [18].
Antibodies were used against RhoB (sc-180), ERa (sc-543)
and, ERb (sc-53494) from Santa Cruz Biotechnology,
phospho-ERa (Ser118, 2511 and Ser167, 2514) from Cell
Signaling (Saint Quentin Yvelines, France), b-actin
(MAB1501) from Chemicon (Merck Millipore; Darmstadt,
Germany), and secondary antibodies were anti-mouse
(MP21120) and anti-rabbit (MP23145) horseradish peroxi-
dase from Interchim (Montluçon, France) using a chemi-
luminescence detection kit (ECL; Pierce, Thermo Fisher
Scientific, Courtaboeuf, France). Protein abundance was
quantified by Image Quant TL analysis (GE Healthcare,
Velizy-Villacoublay, France).
Analysis of mouse embryonic fibroblasts generated from
RhoB-deficient mice
Heterozygous (+/-) and homozygous (-/-) mutant strains
of RhoB-deficient mice [10] were kindly provided by G
Prendergast (Lankenau Institute for Medical Research,
Wynnewood, PA, USA). Claudius Regaud Institute animal
ethics committee approval was obtained (# ICR-2012-001-
A) for the use of the animal model and the study proto-
cols. Mice were housed in polycarbonate cages in con-
trolled conditions. MEFs were generated [10] before lysis
[18]. Protein were extracted and analyzed as described
above with antibody against murine ERa (sc-542) or RhoB
(sc-180; Santa Cruz Biotechnology).
GST pull-down assay
The level of activated RhoB and GTP-bound RhoB protein
was measured using the GST fusion protein containing the
Rho binding domain of Rhotekin [8]. The amount of GTP-
bound RhoB and the total amount of RhoB in cell lysates
were determined by western blot as described above [32].
Immunocytochemistry
For each condition, 5 × 105 cells were seeded onto glass
slides dishes and were grown for 3 days in phenol red-free
DMEM, containing 5% DCC-treated FBS. Cells were then
treated with E2 during 16 hours, washed in PBS and fixed
in RCL2 [33] for 2 minutes. Staining was performed by a
Techmate Horizon™ slide processor as described for
Figure 1. The primary antibody used was a monoclonal
anti-ERa antibody (HC-20, sc-543, dilution 1:50; Santa
Cruz Biotechnology) or an anti-PR antibody (PgR636
clone, dilution 1:50; Dako).
The level of ERa and PR staining was determined by
evaluation of the percentage of tumor-stained cells and
staining intensity, allowing assessment of an IRS.
Quantitative reverse-transcribed PCR
Total RNA was isolated 16 hours after stimulation by E2,
extracted using the RNeasy kit following the manufac-
turer’s instructions (Qiagen, Courtaboeuf, France) and
reverse-transcribed using the iScript™ cDNA Synthesis
Kit (Biorad, Marnes la Coquette, France). Quantitative
PCR was performed with an iQreal-time PCR detection
system (Biorad). The specific human primer pairs used
were: for GAPDH, 5’-TGCACCACCAACTGCTTAGC-3’
and 5’-G GCATGGACTGTGGTCATGAG-3’; for 28s, 5’-
TCGCTGGGTCTTGGATGTC-3’ and 5’-AGCAGATTG
TGACAG ACCATTCC-3’; for PR, 5’-CGCGCTCTAC
CCTGC ACTC-3’ and 5’-TGAATCCGGCCTCAGGT
AGTT-3’; and for ERa, 5’-CCACCAACCAGTGCACC
ATT-3’ and 5’-GGT CTTTTCGTATCCCACCTTTC-3’
(Eurogentec).
Luciferase assay
Development of stable transfectants of MCF-7 cells
(MELN cells) has been described previously [34]. These
cells, kindly provided by P Balaguer (INSERM 540,
France), were established by transfecting MCF-7 cells
with ERE-b-globin-luc-SV-Neo plasmid and thus express
luciferase in an estrogen-dependent manner.
Three days after siRNA transfection, MELN cells were
seeded in DMEM-DCC-treated FBS during 3 days. They
were then treated with E2 or ethanol for 16 hours. Cells
were then lysed in reporter lysis buffer (Promega, Charbon-
nières Les Bains, France). The luciferase activity was mea-
sured with luciferase assay reagent (Promega) according to
the manufacturer’s instructions. Protein concentration was
measured to normalize the luciferase activity data.
Chromatin immunoprecipitation assay
Chromatin immunoprecipitation assays were performed
with modifications of the procedure of Metivier and collea-
gues [35] as described elsewhere [36]. Briefly, 106 cells were
synchronized by 3 days of culture in DMEM 5% DCC-trea-
ted FCS and treated during 1 hour with E2. Immunopreci-
pitation antibodies were ERa (sc-543), HDAC1 (sc-6299),
and polII (sc-899) from Santa Cruz Biotechnology, and
acetylated histone H3 (ab1791) and H4 (ab193) from
Abcam (Paris, France). Quantitative PCR were performed
on an iCycler (Biorad) using the primers 5’-GGCGACAC
AGCAGTGGGGAT-3’ and 5’-TCTCCTC CCTCTGCC
CCTATATTC-3’ (Eurogentec) to amplify the fragment of
the human PR promoter flanking the +745 AP-1 site [37].
Cell growth determination
Forty-eight hours after siRNA transfection or transduc-
tion, cells were seeded in DMEM 5% FBS with ethanol
or E2 and counted daily during the next 4 days with a
coulter counter (Beckman Coulter, Grenoble, France).
Results
RhoB expression correlates positively with receptor status
and negatively with grade in human breast tumors
Using the Oncomine microarray database, a correlation
between RhoB and either ERa or PR expression was
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Figure 1 RhoB, estrogen receptor alpha and progesterone receptor expression in tumor samples of breast cancer patients.
(A) Immunohistochemistry staining shown for two patients, representative of both the estrogen receptor (ER)/progesterone receptor (PR)-
negative and ER/PR-positive populations (×200). (B) Enlargement of the squares represented in (A) (RhoB staining). (C) Medians of RhoB
ImmunoReactive Score (IRS) scores according to ERa and PR positivity, tumor histological grade and tumor size.
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documented in datasets from 19 breast cancer studies.
Moreover, four studies showed an inverse correlation
between RhoB expression and tumor grade. To confirm
the clinical relevance of RhoB expression levels in breast
cancer oncogenesis and outcome, we compared the
expression levels of RhoB in breast carcinomas from a
cohort of 113 patients treated or not by tamoxifen in an
adjuvant setting in a randomized prospective study.
Patient characteristics are described in Table S1 in
Additional file 1. ERa and PR assessments were initially
performed with biochemistry techniques at the time of
diagnosis (between 1980 and 1983). They have all been
performed again at the time of analysis, in parallel with
RhoB assessment. After new pathological analysis, 65
tumors were classified as grade I and II, 74 were ERa-
positive, and 59 were PR-positive. Among these tumors,
23 presented a lymphovascular invasion and 39 cases
presented with positive lymph nodes. After randomiza-
tion, we determined that age, ERa and PR status, histo-
logical grade, and type and lymphovascular invasion
status were similar in the two groups of patients,
whether treated or not. Nonetheless, patients treated
with tamoxifen (n = 62) had less favorable prognostic
factors regarding positive lymph nodes, pathological
tumor size and number of mitoses.
Figure 1A shows the RhoB immunohistochemistry stain-
ings of two representative tumors of patients displaying
opposite hormone receptor status (ERa/PR-negative and
ERa/PR-positive), illustrating the direct correlation
between RhoB and both ERa and PR expression. Enlarge-
ment of the photographs (Figure 1B) illustrates in the
tumor cells of the ERa/PR-negative patient that RhoB is
present and specifically cytoplasmic, although the staining
is weak. For the ERa/PR-positive patient, in addition to
cytoplasmic staining, a strong staining was also observed
at nucleus level.
Statistical analysis of the results indicated that RhoB
expression in tumors is strongly correlated with the per-
centage of ERa (Spearman’s r = 0.3659, P = 0.001) and
PR (r = 0.2544, P = 0.0076) expression, but inversely cor-
related with histological tumor size (r = -0.2344, P =
0.0166) and number of mitoses (r = -0.2009, P = 0.0362).
We divided the patients with ERa-positive tumors into
two groups with either low or high RhoB expression, and
in each group we further divided the patients into groups
that did or did not receive tamoxifen. This analysis
argued that the level of RhoB expression was not corre-
lated with disease-free survival of patients with ERa-posi-
tive tumors, regardless of tamoxifen treatment or not
(Kaplan-Meier curve shown in Figure S1 in Additional
file 3).
The RhoB IRS (see Materials and methods) integrat-
ing both the percentage and intensity of the staining
(Figure 1C) was significantly higher in ERa-positive tumors
(median 10.5 (3 to 12)) as compared with ERa-negative
tumors (median 8 (1 to 12)), in PR-positive tumors (median
9 (3 to 12)) as compared with PR-negative tumors (median
8 (1 to 12)), and in patients with tumor grade I and II
(median 9 (3 to 12)) as compared with grade III (median 8
(1 to 12)). The line in the center of each box represents the
median value of the distribution, and the upper and lower
ends of the box are the upper and lower quartiles, respec-
tively. The RhoB level of expression was also higher in the
smaller tumor size (≤ 2 cm, median 12 (2 to 12)) as com-
pared with larger tumors (> 2 cm, median 8 (1 to 12)). The
RhoB IRS score was not correlated with the presence of
lymphovascular invasion (P = 0.26), nor with the presence
of lymph node invasion (P = 0.74).
RhoB regulates ERa expression in MCF-7, in vivo and in
other breast cancer cell lines
We confirmed the expectation of an effect of RhoB on
ERa expression in MCF-7 cells in the presence of E2,
using two different siRNA sequences to target RhoB
mRNA (siB1 and siB2) (Figure 2A, left panel). We
observed associated decreases in ERa expression of 60%
and 62% (siB1 and siB2, respectively). This result was con-
firmed using two other independent siRNA sequences tar-
geting RhoB (data not shown).
To rule out the possibility of off-target effects of the
siRNA approach, we transduced MCF-7 cells with an
adenoviral vector expressing RhoB (Figure 2A, right
panel). The observed 4.5-fold overexpression of RhoB
increased the expression of ERa (186%), further support-
ing the hypothesized regulatory relationship.
We extended the study of RhoB downregulation on ERa
expression to additional cell lines (Figure S2 in Additional
file 4), confirming a decrease of ERa expression with
RhoB depletion using siB1 and siB2 in T47D and ZR75
cells (hormone-dependent cells) or in LCC2 cells (hor-
mone-resistant cells). We confirmed the involvement of
RhoB on ERa expression in vivo using mice that are
genetically deficient in RhoB (Figure 2B). A major decrease
of ERa expression was visualized in MEFs collected from
RhoB+/- mice with an even more dramatic decrease in
MEFs collected from RhoB-/- mice. These results extended
the support for a hypothesized regulatory relationship
between RhoB and ERa.
We also studied the levels of ERa phosphorylated
forms whose involvement as prognostic markers is dis-
cussed below (Figure 2C). We observed that the decrease
of ERa expression observed when RhoB expression is
downregulated is not associated with any significant spe-
cific change of P-Ser118 or P-Ser167 ERa level. Indeed, the
ratio phosphorylated/total ERa is not modified after
RhoB inhibition.
We then demonstrated that ERa expression is dramati-
cally decreased in the presence of the pure anti-estrogen
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ICI-182, 780, even when RhoB is overexpressed (Fig-
ure 2D).
Estrogen induces RhoB activation
In examining the effect of estrogen on RhoB expression
and activity and given that the activation of RhoB is
important for its physiological effect [8,18,20], we inves-
tigated the role of estrogen stimulation on the RhoB
guanine nucleotide binding status (Figure 3A) to analyze
rapid effects of E2 stimulation on RhoB activation as
well as expression. We observed that RhoB is quickly
activated at 30 minutes without any change of total
RhoB expression, as described with epidermal growth
factor stimulation [8,20]. At 1 hour and 2 hours of
treatment, E2 rapidly increased the total RhoB expres-
sion with a second peak of GTP-bound RhoB occurring
at 2 hours associated with a parallel increase of total
RhoB expression.
Together these results suggested that RhoB and estro-
gen signaling are integrated into a feed-forward loop that
may positively modify the biological effects of estrogen
treatment.
RhoB regulates ERa, but not ERb, expression in the
absence and presence of estradiol in MCF-7 cells
We analyzed further the effect of RhoB downregulation
on ERa and ERb expression in the absence and presence
of E2 (Figure 3B). As expected, E2 treatment induced a
Figure 2 Regulation of estrogen receptor alpha expression by RhoB in MCF-7 cells and in vivo. (A) Cells were transfected with siControl
(siC), siB1 or siB2 (left panel) or transduced with adenoviral vectors (multiplicity of infection (MOI) 300:1) (right panel) during 48 hours. (B) Mouse
embryonic fibroblasts (MEFs) of RhoB-deficient mice were lysed. (C) MCF-7 cells were transfected with siC or siB2. Estrogen receptor alpha (ERa)
phosphorylation was analyzed 48 hours later. (D) Cells were transduced with adenoviral vectors (MOI 300:1) during 48 hours, and 3 days later
were treated by ICI-182, 780 or ethanol during 16 hours. (A) to (D) Protein expression was analyzed. Representative of three independent
experiments. AdC, adenoviral control empty vector.
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major significant decrease of ERa expression and concomi-
tantly of RhoB expression. In the presence of siB2, a 36 to
41% decrease of ERa expression was observed in the
absence of E2 and 48 to 52% in the presence of E2. In con-
trast, ERb expression was not clearly altered by RhoB
downregulation (Figure 3B). Using immunocytochemistry,
we confirmed these results suggesting that RhoB regulates
ERa expression and observed no dramatic changes of RhoB
subcellular localization within MCF-7 cells (Figure 3C).
ERa was highly concentrated in the nucleus of the
untreated control with a significant staining of the related
cytoplasm. In the presence of E2, the staining intensities of
both nuclei and cytoplasms were clearly decreased with no
more detectable staining in the cytoplasm, confirmed by
IRS assessment. For siB2-treated cells, a similar major
decrease of the labeling intensity was observed in the
Figure 3 RhoB activation and regulation of estrogen receptor alpha expression with/without estradiol in MCF-7 cells. (A) Cells were
deprived of estradiol (E2) for 3 days and then treated by E2 or epidermal growth factor (EGF) during the indicated times. GTP-bound RhoB and
total lysates were collected. Protein expression was then analyzed. Representative of three to four independent experiments. (B) to (D) Cells were
transfected with siControl (siC) or siB2, and 3 days later were deprived of E2 for 3 additional days and treated for 16 hours with E2 or ethanol. (B)
Protein expression was then analyzed. Representative of three independent experiments. (C) Estrogen receptor alpha (ERa) expression was
analyzed by immunocytochemistry. ImmunoReactive Score (IRS) shown in the upper-right corner. Representative of three independent
experiments. (D) Expression of the ERa gene was then measured. Error bars represent the mean values ± standard deviation from triplicate
conditions, representative of two independent experiments. Differences were considered statistically significant at *P < 0.01, Student’s t test.
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cytoplasm and the nucleus, both in the presence and the
absence of E2. In the presence of E2, the IRS score was
maintained at a value of 2 because, in spite of the difference
from 30 to 20% of stained cells induced by siB2 treatment,
the intensity is kept very low in both cases (value of 1).
We then investigated whether RhoB downregulation
modulates ERa mRNA expression (Figure 3D). We first
confirmed the expected decrease of ERa mRNA expres-
sion in control cells treated by E2 alone (to 0.49). In the
cells treated with siB2, a dramatic decrease of ERa mRNA
was observed in the absence of E2 (from 1 to 0.53) and
much lighter in the presence of E2 (from 0.49 to 0.37).
RhoB promotes ERa transcriptional activation function
induced by estrogen
We hypothesized that the ability of RhoB to modulate ERa
expression could control the major transcriptional func-
tions of ERa. To examine this hypothesis, we used MELN
cells that express luciferase in an estrogen-dependent
manner. After siB1 or siB2 transfection and E2 deprivation,
cells were treated or not with E2 and luciferase activity was
quantified (Figure 4A). In the absence of E2 (upper-right
corner), the transfection of cells by both siB1 and siB2
induced a significant decrease of the luciferase activity
(0.5-fold for B1 and 0.7-fold for B2). In the control cells,
E2 treatment led to a ninefold induction of the luciferase
activity. In the presence of E2, luciferase expression was
significantly decreased for cells treated by the siB1 and
siB2 sequences (respectively 3.12 and 4.07 compared with
9 AU). Nonetheless, E2 induction was still observed for all
cells transfected by either siB1 or siB2. We extended
the analysis of RhoB inhibition on two known estrogen-
regulated genes, ERa itself described above (Figure 3D)
and PR, using quantitative RT-PCR (Figure 4B).
Regarding PR, a major target gene of ERa, PR mRNA
expression was induced in the presence of E2 (7.7-fold) in
the siRNA control cells (Figure 4B). In cells treated with
siB1, there was a significant decrease of PR mRNA levels
as compared with their respective control, both without
and with E2 (rates 0.5 and 0.6, respectively). Consequently,
E2 induction was maintained for cells transfected by both
siRNA control and siB1 (respectively 7.7-fold and
ninefold).
Using immunocytochemistry, we confirmed that RhoB
regulates ERa (Figure 3C) plus PR (Figure 4C) expres-
sion, with no dramatic changes of their subcellular locali-
zation within MCF-7 cells. PR is mainly detected in the
nuclei of the untreated control. Besides, the presence of
siB2 again significantly decreases IRS scores both in the
absence and presence of E2.
Cells treated with siB2 exhibit low levels of ERa protein
and mRNA in both the absence and presence of E2
(Figure 3B, C, D). Nonetheless, the effects of RhoB on
PR expression may be supported in part by other
mechanisms. We used chromatin immunoprecipitation
analysis to study the effect of RhoB inhibition on the
recruitment of ERa, ER transcriptional co-factors and
RNA polymerase II onto PR gene promoter 1 hour after
E2 stimulation (Figure 4D). Following siB1 transfection,
the recruitment of RNA polymerase II to the PR gene
promoter dramatically decreased (rate 0.3 compared with
siControl). Recruitment of acetylated H3 and H4 histones
were also clearly decreased by RhoB downregulation
(rates 0.36 and 0.33, respectively). Moreover, RhoB
downregulation induced a significant decrease in the
recruitment of ER to the PR gene promoter (rate 0.52)
paralleled by an increased in recruitment of the ERa co-
repressor HDAC1 (rate 1.67). Together, these results
indicate that RhoB may support to some extent ERa
transcriptional activation function by interfering with its
cofactor recruitment, besides the direct effect on ERa
expression itself.
RhoB induces proliferation in ER-positive but not in
ER-negative breast cancer cell lines
The effect of RhoB on cell proliferation was evaluated in
three cell lines exhibiting variable levels of expression of
ERa, including MCF-7 (ERa/PR-positive), SK-BR-3 (ERa/
PR-negative and p185erbB2 overexpressed) and MDA-MB-
231 (ERa/PR-negative and p185erbB2-negative). As shown
in Figure 5A, B, RhoB positively regulated the proliferation
of MCF-7 cells both in the absence or presence of E2.
siRNA-mediated inhibition of RhoB expression produced
a 30 to 35% decrease in MCF-7 cell proliferation as soon
as 1 day after transfection, with a 40 to 46% decrease by
day 4 (Figure 5A). Conversely, a significant increase in cell
proliferation was observed in MCF-7 cells transduced with
an adenoviral vector expressing RhoB (Figure 5B), with an
increase of 15 to 28% in relative cell proliferation at day 1
that reached 22 to 49% by day 4. In contrast to these
observations, under similar conditions for infection of SK-
BR-3 or MDA-MB-231 cells, the adenoviral RhoB vector
either slightly decreased or had no significant biological
effect on cell proliferation (Figure 5C, D). The effect of
RhoB downregulation was also analyzed in LCC2 cells, an
E2-independent, tamoxifen-resistant subline of the MCF-7
cells. As for the MCF-7 cells, a significant decrease of pro-
liferation was observed at day 4, in parallel to ERa and
RhoB downregulation (see Figures S2 and S3 in Additional
files 4 and 5).
In conclusion, we documented that RhoB had stimula-
tory effects on proliferation via ERa signaling that paral-
leled its effects on hormone receptor expression.
Discussion
Although the tumor suppressor function of RhoB has
been documented in many human cancers [11,12], RhoB
overexpression was suggested to be associated with
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tumor progression in breast cancers. Using cellular and
human breast tumor analytical approaches, we have
shown a positive crosstalk between RhoB and ERa expres-
sion and the critical role of RhoB in regulation of the pro-
liferation of ERa-expressing breast cancer cells.
Our data bring together three lines of evidence to sup-
port the crosstalk between ERa and RhoB. First, in human
breast cancer tissues we clearly showed a strong correla-
tion between RhoB expression and the expression of ERa
and PR. Moreover RhoB expression was associated with a
Figure 4 RhoB downregulation effect on estrogen receptor alpha-dependent transcription and recruitment of cofactors on PR
promoter. MELN or MCF-7 cells were transfected with siControl (siC), siB1 or siB2, and 3 days later were deprived of estradiol (E2) for
3 additional days. (A) MELN cells were then treated for 16 hours with E2 or ethanol. Luciferase activity was quantified and normalized. Error bars
represent the mean values ± standard deviation (SD) from four independent experiments. Data generated in the absence of E2 are enlarged in
the upper-right corner. (B) MCF-7 cells were then treated for 16 hours with E2 or ethanol and expression of the PR gene was measured. Error
bars represent the mean values ± SD from three independent experiments. (C) MCF-7 cells were then treated for 16 hours with E2 or ethanol
and progesterone receptor (PR) expression was analyzed by immunocytochemistry. ImmunoReactive Score (IRS) shown in the upper-right corner.
Representative, respectively, of four and three independent experiments. (D) MCF-7 cells were treated for 1 hour with E2 and lysed for chromatin
immunoprecipitation (ChIp) experiments using indicated antibodies. Specificity of the immunoprecipitation was controlled using nonspecific
rabbit IgG. Recruitment of these proteins on the PR promoter was quantified. The fold induction for the recruitment of siB1 versus siC conditions
was calculated. Error bars represent the mean values ± SD from three independent experiments. Differences were considered statistically
significant at *P < 0.01 and **P < 0.001, Student’s t test.
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low tumor grade and size, suggesting that RhoB expression
is correlated with good prognosis markers. The second
strand of evidence came from cellular results showing that
the level of RhoB controls the expression of ERa in ERa-
positive breast cancer cell in the presence or absence of E2.
The positive modulation of ERa expression by RhoB was
evidenced both at the protein and mRNA levels. We
showed that the ERa mRNA level is controlled by RhoB,
suggesting that transcriptional regulation could play a key
role in this regulation. The phosphorylation of Ser167 of
ERa in tumors has been related to longer overall survival
whereas the phosphorylation of Ser118 could be a good
Figure 5 RhoB differentially affects the proliferation of breast cancer cell lines. Forty-eight hours after transfection or transduction, cells
were seeded with estradiol (E2) or ethanol and counted daily. Error bars represent the mean values ± standard deviation from three
independent experiments that generated triplicate data each. (A) MCF-7 cells were transfected with siControl (siC) or siB1. (B) MCF-7 cells,
(C) SK-BR-3 cells and (D) MDA-MB-231 cells were transduced with adenoviral vectors (multiplicity of infection 100:1). Control western blot
experiments are shown in the presence of E2. According to the Kruskal-Wallis test, differences were considered statistically significant at *P < 0.01
and **P < 0.001 by comparing siB1 or adenoviral vector expressing RhoB (AdB) conditions with the related control condition (either in
the presence or absence of E2). The significance threshold was determined at 0.0125 using Bonferroni correction. AdC, adenoviral control
empty vector.
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prognostic marker [38,39]. We found a dramatically
decreased level of ERa phosphorylation at both serine sites
that can be attributed to the major decrease in total ERa
expression (RhoB downregulation induced no significant
change in the phosphorylated/total ERa ratio). Third, we
clearly demonstrated in vivo the RhoB control of ERa
expression in MEF cells derived from a RhoB-/- mouse
model. This regulation is of interest in the context of the
epithelial-stromal interactions, particularly given that breast
adipose fibroblasts determine the expression of aromatase
[40]. Further, we demonstrated that ERa controls the acti-
vation and expression of RhoB. Notably, E2 treatment
induces an increase of active GTP-RhoB within 30 min-
utes, without changing RhoB expression at that time.
ERa upregulates or downregulates the transcription of
hundreds of genes [41] and PR is a well-known ERa target
gene with a major physiological role in cell proliferation.
Both PR mRNA and protein expression were significantly
decreased as a consequence of RhoB and related ERa
downregulations. Further findings evidenced a clear
decrease of the recruitment of RNA polymerase II, acety-
lated H3/H4 histones and ERa onto the promoter of the
PR gene. In parallel, we described the recruitment of the
major transcriptional co-repressor HDAC1, which is
known to repress RhoB expression [42]. These results pro-
vide the demonstration of a regulatory role for RhoB in
ERa expression and in the balance of the associated co-
regulators of ERa to control transcription of its target
genes. The possibility of a direct interaction of RhoB with
the ERa-dependent transcriptional machinery should not
be excluded since a direct interaction between ERa and
RhoGDIa in breast cancer cells has been demonstrated
[30] and we have shown here a strong nuclear localization
of RhoB in ERa-positive tumor tissues.
In contrast to other cancer models, RhoB is critical for
the proliferation of ERa-expressing breast cancer cells,
suggesting its role as a positive regulator in this model. It
is noteworthy that the RhoB effect is also observed on the
proliferation of the ERa-positive, tamoxifen-resistant
LCC2 model cell line. Inversely, in ERa-negative cell lines
(SK-BR-3 and MDA-MB-231), RhoB has no effect on pro-
liferation - thus reinforcing the idea that RhoB promotes
cell proliferation through ERa expression. These results
suggest that RhoB downregulation in breast cancer cells
could be associated with tumor progression in parallel to
ERa extinction, with a chronology that remains to be
elucidated.
Conclusion
We have demonstrated that RhoB GTPase is a key indu-
cer of ERa and a key regulator of PR expression. RhoB
acts through various complex mechanisms underlying a
feed-forward loop that may control estrogen effects,
including cell proliferation. Our new findings shed light
on the role of RhoB in tumorigenesis involving a dual
effect conferred by cellular context with a potential pro-
oncogenic function in hormone-dependent breast cancer
cells.
Additional material
Additional file 1: Table S1 presenting clinicopathological
characteristics of 113 breast cancer patients.
Additional file 2: A word file presenting the supplementary
materials and methods, with information for the patient population
and the proliferation determination in LCC2 cells.
Additional file 3: Figure S1 showing Kaplan-Meier representation of
DFS for the patients according to RhoB expression (low or high) in
their tumors.
Additional file 4: Figure S2 showing RhoB downregulation is
associated with decreases of ERa expression in three other breast
cancer cell lines. T47D, ZR75 and LCC2 cells were transfected with
siControl (siC), siB1 or siB2 during 48 hours. Protein expression was then
analyzed. Representative of two to three independent experiments.
Additional file 5: Figure S3 showing RhoB downregulation is
associated with decreased proliferation in LCC2 cells. The LCC2 cells
were transfected with siControl (siC) or siB1, and the cells were seeded
48 hours after transfection and counted at day 4. Error bars represent the
mean values ± standard deviation from triplicate data. Representative of
two independent experiments.
Abbreviations
DCC: dextran-coated charcoal; DMEM: Dulbecco’s modified Eagle’s medium;
E2: estradiol; ER: estrogen receptor; FBS: fetal bovine serum; IRS:
ImmunoReactive Score; MEF: mouse embryonic fibroblast; PCR: polymerase
chain reaction; PR: progesterone receptor; RT: reverse transcriptase; siRNA:
small interfering RNA.
Authors’ contributions
GF and SFD-S are co-last authors of this work. CM-G and IL-M carried out
the cell line experiments and reviewed the manuscript, EMa carried out
western blot, luciferase and GST pull-down experiments and participated in
drafting the manuscript. EMe carried out chromatin immunoprecipitation,
RT-PCR, western blot and proliferation experiments and participated in
drafting the manuscript. BC participated in the adenovirus experiments. YB
participated in immunocytochemistry experiments. TF performed all
statistical analysis. LK carried out the patient data collection. CM carried out
the tissue microarray. ML-T performed the tissue microarray analysis and
reviewed the manuscript. FD participated in the design of the study and
reviewed the manuscript. SFD-S conceived the study, coordinated the study
and drafted the manuscript. GF coordinated the study and reviewed the
manuscript. All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Acknowledgements
This work was supported by the National Institute of Cancer, Canceropole
Grand Sud-Ouest, Fondation RITC (C Silvagni), INSERM, Claudius Regaud
Institute, University of Toulouse (UPS) and the French Ministry of Research
(MRES). Thanks are due to GC Prendergast for fruitful discussion and
reviewing the manuscript.
Author details
1INSERM U563 and UMR1037, Institut Claudius Regaud, 20-24 rue du pont St
Pierre, Toulouse cedex 31052, France. 2Faculté des Sciences
Pharmaceutiques, Université Paul Sabatier Toulouse III, Toulouse cedex
31062, France. 3EA4553, Institut Claudius Regaud, 20-24 rue du pont St
Pierre, Toulouse cedex 31052, France. 4Département de Biologie et de
Médale-Giamarchi et al. Breast Cancer Research 2013, 15:R6
http://breast-cancer-research.com/content/15/1/R6
Page 11 of 13
Pathologie, Institut Claudius Regaud, 20-24 rue du pont St Pierre, Toulouse
cedex 31052, France. 5Tumorbiologischen Labor, Klinikum der Ludwig-
Maximilians-Universität, Maistraße 11, München 80337, Germany.
Received: 6 August 2012 Revised: 22 November 2012
Accepted: 10 January 2013 Published: 22 January 2013
References
1. Musgrove EA, Sutherland RL: Biological determinants of endocrine
resistance in breast cancer. Nat Rev Cancer 2009, 9:631-643.
2. Miller TW, Balko JM, Arteaga CL: Phosphatidylinositol 3-kinase and
antiestrogen resistance in breast cancer. J Clin Oncol 2011, 29:4452-4461.
3. Fox EM, Andrade J, Shupnik MA: Novel actions of estrogen to promote
proliferation: integration of cytoplasmic and nuclear pathways. Steroids
2009, 74:622-627.
4. Guilluy C, Garcia-Mata R, Burridge K: Rho protein crosstalk: another social
network? Trends Cell Biol 2011, 21:718-726.
5. Jaffe AB, Hall A: Rho GTPases in transformation and metastasis. Adv
Cancer Res 2002, 84:57-80.
6. Jahner D, Hunter T: The ras-related gene rhoB is an immediate-early
gene inducible by v-Fps, epidermal growth factor, and platelet-derived
growth factor in rat fibroblasts. Mol Cell Biol 1991, 11:3682-3690.
7. de Cremoux P, Gauville C, Closson V, Linares G, Calvo F, Tavitian A,
Olofsson B: EGF modulation of the ras-related rhoB gene expression in
human breast-cancer cell lines. Int J Cancer 1994, 59:408-415.
8. Gampel A, Mellor H: Small interfering RNAs as a tool to assign Rho
GTPase exchange-factor function in vivo. Biochem J 2002, 366:393-398.
9. Karlsson R, Pedersen ED, Wang Z, Brakebusch C: Rho GTPase function in
tumorigenesis. Biochim Biophys Acta 2009, 1796:91-98.
10. Liu AX, Rane N, Liu JP, Prendergast GC: RhoB is dispensable for mouse
development, but it modifies susceptibility to tumor formation as well
as cell adhesion and growth factor signaling in transformed cells.
Mol Cell Biol 2001, 21:6906-6912.
11. Adnane J, Muro-Cacho C, Mathews L, Sebti SM, Munoz-Antonia T:
Suppression of rho B expression in invasive carcinoma from head and
neck cancer patients. Clin Cancer Res 2002, 8:2225-2232.
12. Mazieres J, Antonia T, Daste G, Muro-Cacho C, Berchery D, Tillement V,
Pradines A, Sebti S, Favre G: Loss of RhoB expression in human lung
cancer progression. Clin Cancer Res 2004, 10:2742-2750.
13. Zhou J, Zhu Y, Zhang G, Liu N, Sun L, Liu M, Qiu M, Luo D, Tang Q, Liao Z,
Zheng Y, Bi F: A distinct role of RhoB in gastric cancer suppression.
Int J Cancer 2011, 128:1057-1068.
14. Lebowitz PF, Davide JP, Prendergast GC: Evidence that farnesyltransferase
inhibitors suppress Ras transformation by interfering with Rho activity.
Mol Cell Biol 1995, 15:6613-6622.
15. Zalcman G, Closson V, Linares-Cruz G, Lerebours F, Honore N, Tavitian A,
Olofsson B: Regulation of Ras-related RhoB protein expression during the
cell cycle. Oncogene 1995, 10:1935-1945.
16. Gampel A, Parker PJ, Mellor H: Regulation of epidermal growth factor
receptor traffic by the small GTPase rhoB. Curr Biol 1999, 9:955-958.
17. Engel ME, Datta PK, Moses HL: RhoB is stabilized by transforming growth
factor beta and antagonizes transcriptional activation. J Biol Chem 1998,
273:9921-9926.
18. Skuli N, Monferran S, Delmas C, Lajoie-Mazenc I, Favre G, Toulas C, Cohen-
Jonathan-Moyal E: Activation of RhoB by hypoxia controls hypoxia-
inducible factor-1α stabilization through glycogen synthase kinase-3 in
U87 glioblastoma cells. Cancer Res 2006, 66:482-489.
19. Fritz G, Kaina B, Aktories K: The ras-related small GTP-binding protein
RhoB is immediate-early inducible by DNA damaging treatments.
J Biol Chem 1995, 270:25172-25177.
20. Canguilhem B, Pradines A, Baudouin C, Boby C, Lajoie-Mazenc I,
Charveron M, Favre G: RhoB protects human keratinocytes from UVB-
induced apoptosis through epidermal growth factor receptor signaling.
J Biol Chem 2005, 280:43257-43263.
21. Srougi MC, Burridge K: The nuclear guanine nucleotide exchange factors
Ect2 and Net1 regulate RhoB-mediated cell death after DNA damage.
PLoS One 2011, 6:e17108.
22. Tang Y, Olufemi L, Wang MT, Nie D: Role of Rho GTPases in breast cancer.
Front Biosci 2008, 13:759-776.
23. Fritz G, Brachetti C, Bahlmann F, Schmidt M, Kaina B: Rho GTPases in
human breast tumours: expression and mutation analyses and
correlation with clinical parameters. Br J Cancer 2002, 87:635-644.
24. Jiang WG, Watkins G, Lane J, Cunnick GH, Douglas-Jones A, Mokbel K,
Mansel RE: Prognostic value of rho GTPases and rho guanine nucleotide
dissociation inhibitors in human breast cancers. Clin Cancer Res 2003,
9:6432-6440.
25. Lane J, Martin TA, Mansel RE, Jiang WG: The expression and prognostic
value of the guanine nucleotide exchange factors (GEFs) Trio,
Vav1 and TIAM-1 in human breast cancer. Int Semin Surg Oncol 2008,
5:23.
26. Stebel A, Brachetti C, Kunkel M, Schmidt M, Fritz G: Progression of breast
tumors is accompanied by a decrease in expression of the Rho guanine
exchange factor Tiam1. Oncol Rep 2009, 21:217-222.
27. Ronneburg H, Span PN, Kantelhardt E, Dittmer A, Schunke D,
Holzhausen HJ, Sweep FC, Dittmer J: Rho GDP dissociation inhibitor alpha
expression correlates with the outcome of CMF treatment in invasive
ductal breast cancer. Int J Oncol 36:379-386.
28. Rubino D, Driggers P, Arbit D, Kemp L, Miller B, Coso O, Pagliai K, Gray K,
Gutkind S, Segars J: Characterization of Brx, a novel Dbl family member
that modulates estrogen receptor action. Oncogene 1998, 16:2513-2526.
29. Su LF, Knoblauch R, Garabedian MJ: Rho GTPases as modulators of the
estrogen receptor transcriptional response. J Biol Chem 2001,
276:3231-3237.
30. El Marzouk S, Schultz-Norton JR, Likhite VS, McLeod IX, Yates JR,
Nardulli AM: Rho GDP dissociation inhibitor alpha interacts with estrogen
receptor alpha and influences estrogen responsiveness. J Mol Endocrinol
2007, 39:249-259.
31. Couderc B, Pradines A, Rafii A, Golzio M, Deviers A, Allal C, Berg D,
Penary M, Teissie J, Favre G: In vivo restoration of RhoB expression leads
to ovarian tumor regression. Cancer Gene Ther 2008, 15:456-464.
32. Lajoie-Mazenc I, Tovar D, Penary M, Lortal B, Allart S, Favard C, Brihoum M,
Pradines A, Favre G: MAP1A light chain-2 interacts with GTP-RhoB to
control epidermal growth factor (EGF)-dependent EGF receptor
signaling. J Biol Chem 2008, 283:4155-4164.
33. Delfour C, Roger P, Bret C, Berthe ML, Rochaix P, Kalfa N, Raynaud P,
Bibeau F, Maudelonde T, Boulle N: RCL2, a new fixative, preserves
morphology and nucleic acid integrity in paraffin-embedded breast
carcinoma and microdissected breast tumor cells. J Mol Diagn 2006,
8:157-169.
34. Balaguer P, Francois F, Comunale F, Fenet H, Boussioux AM, Pons M,
Nicolas JC, Casellas C: Reporter cell lines to study the estrogenic effects
of xenoestrogens. Sci Total Environ 1999, 233:47-56.
35. Metivier R, Penot G, Hubner MR, Reid G, Brand H, Kos M, Gannon F:
Estrogen receptor-alpha directs ordered, cyclical, and combinatorial
recruitment of cofactors on a natural target promoter. Cell 2003,
115:751-763.
36. Baron S, Escande A, Alberola G, Bystricky K, Balaguer P, Richard-Foy H:
Estrogen receptor alpha and the activating protein-1 complex cooperate
during insulin-like growth factor-I-induced transcriptional activation of
the pS2/TFF1 gene. J Biol Chem 2007, 282:11732-11741.
37. Petz LN, Ziegler YS, Schultz JR, Kim H, Kemper JK, Nardulli AM: Differential
regulation of the human progesterone receptor gene through an
estrogen response element half site and Sp1 sites. J Steroid Biochem Mol
Biol 2004, 88:113-122.
38. Jiang J, Sarwar N, Peston D, Kulinskaya E, Shousha S, Coombes RC, Ali S:
Phosphorylation of estrogen receptor-alpha at Ser167 is indicative of
longer disease-free and overall survival in breast cancer patients. Clin
Cancer Res 2007, 13:5769-5776.
39. Murphy LC, Niu Y, Snell L, Watson P: Phospho-serine-118 estrogen
receptor-alpha expression is associated with better disease outcome in
women treated with tamoxifen. Clin Cancer Res 2004, 10:5902-5906.
40. Bulun SE, Lin Z, Zhao H, Lu M, Amin S, Reierstad S, Chen D: Regulation of
aromatase expression in breast cancer tissue. Ann N Y Acad Sci 2009,
1155:121-131.
41. Carroll JS, Meyer CA, Song J, Li W, Geistlinger TR, Eeckhoute J,
Brodsky AS, Keeton EK, Fertuck KC, Hall GF, Wang Q, Bekiranov S,
Sementchenko V, Fox EA, Silver PA, Gingeras TR, Liu XS, Brown M:
Genome-wide analysis of estrogen receptor binding sites. Nat Genet
2006, 38:1289-1297.
Médale-Giamarchi et al. Breast Cancer Research 2013, 15:R6
http://breast-cancer-research.com/content/15/1/R6
Page 12 of 13
42. Wang S, Yan-Neale Y, Fischer D, Zeremski M, Cai R, Zhu J, Asselbergs F,
Hampton G, Cohen D: Histone deacetylase 1 represses the small GTPase
RhoB expression in human nonsmall lung carcinoma cell line. Oncogene
2003, 22:6204-6213.
doi:10.1186/bcr3377
Cite this article as: Médale-Giamarchi et al.: RhoB modifies estrogen
responses in breast cancer cells by influencing expression of the
estrogen receptor. Breast Cancer Research 2013 15:R6.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Médale-Giamarchi et al. Breast Cancer Research 2013, 15:R6
http://breast-cancer-research.com/content/15/1/R6
Page 13 of 13
